Systematic Engineering Approach to Development and Identification of Physiologically-Based Pharmacokinetic Models by Hall, Cierra et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 19, 2017
Systematic Engineering Approach to Development and Identification of
Physiologically-Based Pharmacokinetic Models
Hall, Cierra; Sin, Gürkan; Gani, Rafiqul; Linninger, Andreas
Publication date:
2011
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Hall, C., Sin, G., Gani, R., & Linninger, A. (2011). Systematic Engineering Approach to Development and
Identification of Physiologically-Based Pharmacokinetic Models. Abstract from 2011 AIChE Annual Meeting,
Minneapolis, MN, United States.
Abstract: Systematic Engineering Approach to Development and Identification of Physiologically-Based Pharmacokinetic Models (2011 Annual Meeting)
http://aiche.confex.com/aiche/2011/webprogram/Paper236436.html[28-10-2011 15:41:55]
Start | Grid View | Browse by Day OR Group/Topical | Author Index | Keyword Index | Personal Scheduler
Systematic Engineering Approach to Development and Identification of
Physiologically-Based Pharmacokinetic Models
Wednesday, October 19, 2011: 4:27 PM
101 H (Minneapolis Convention Center)
Cierra Hall1, Martina Heitzig2, Gürkan Sin2, Rafiqul Gani2 and Andreas Linninger1, (1)Laboratory for Product and Process
Design, University of Illinois at Chicago, Chicago, IL, (2)Department of Chemical and Biochemical Engineering, Technical
University of Denmark, Kgs. Lyngby, Denmark
Whole body physiologically-based pharmacokinetic (PBPK) modeling attempts to model the uptake and distribution of a drug
inside the body. Traditionally, pharmacokinetic models have been developed by simple curve fitting of experimental data without
considering the mechanistic and physics of the system. The drawback of such models is their lack of physical insights and the
pure extrapolation features to untested conditions, to other drugs as well as to individuals of the same species or different species.
Lately, PBPK models, which are based on first principles, have received increasing attention. In this work, a first principles
engineering approach to PBPK modeling that is based on conservation equations and advanced scaling laws is proposed. The
developed global pharmacokinetic models are based on biochemical, anatomical and physiological data.
The resulting PBPK models are able to extrapolate and scale between species and individuals because they are based on actual
occurring physical mechanisms and allow the application of more advanced scaling laws than just considering the differing masses
of the individuals. Due to their improved scaling qualities, first principles PBPK models have the potential to reduce the number of
undesirable as well as time- and cost-intensive animal experiments during the drug development phase. Further, the development
of first principle-based PBPK models leads to a gain of insight in the occurring processes during drug uptake by an organism.
Having these models at hand moreover allows the determination of accurate and optimal drug dosage for desired therapeutic
effects.
However, the development of first principles PBPK models, their identification, and discrimination between different candidate
models is a non-trivial task inherent with a number of challenges which are related to identifying the occurring mechanisms inside
the body and the appropriate degrees of detail of the models with respect to the modeling goal and the available experimental
data:
Firstly, a large number of alternative PBPK models can be generated depending on the degree of detail considered and the
assumptions made about the different considered mechanisms in the body. Further, first principle PBPK models are usually
complex models which contain a large number of unknown parameters that are not always all identifiable by the limited
experimental data accessible. A strategy needs to be found to address the problem of discriminating between the different
candidate models and identifying their parameters in order to find the model that is best supported by the experimental data
available. In this context, design of experiments for model discrimination and parameter estimation plays an important role. If the
models cannot be discriminated based on the available data, or model parameters that are important for the desired model outputs
are not identifiable by the available data, methods for optimal design of experiments need to be applied. Design of experiments is
especially important in pharmacokinetic modeling because in order to obtain the required datapoints animals need to be sacrificed.
In this work, a systematic methodology for the development, analysis, identification (including sensitivity analysis, identifiability
analysis and parameter estimation) and discrimination between different pharmacokinetic candidate models is proposed. The
methodology is implemented into a computer-aided modeling framework. The benefit of the proposed systematic approach is an
improvement of model quality and an increase of efficiency of the modeler as well as the experimentalist and thereby a reduction
of time and resources required for model development, identification, discrimination and application. This is achieved by designing
the structure of the computer-aided modeling framework such that it can handle the work-flows and data-flows associated with the
different modeling tasks, combining state-of-the-art modeling techniques for the different work-flow steps as well as supporting
model-documentation and model reuse.
The proposed modeling framework for PBPK modeling is highlighted through a case study which deals with the development of a
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PBPK model for a rat based on available experimental data.
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